TIGIT-high CD8+ T cells presented as functionally impaired and exhausted, whereas TIGIT blockade rescued functionality and anti-tumor response, highlighting TIGIT blockade as a potential therapeutic approach for leukemia. The gene discussed is CD8A; the disease is neoplasm.